初次经直肠超声引导活检良性男性的前列腺癌诊断与死亡风险:一项基于人群的研究
该研究基于丹麦前列腺癌登记处,纳入1995年1月1日至2011年12月31日转诊行经直肠超声引导活检的63454名男性,随访至2015年4月28日。初次活检良性者20年前列腺癌特异性死亡累积发生率为5.2%(95%CI 3.9-6.5),其他原因死亡为59.9%(95%CI 55.2-64.6)。
要点
- 初次活检良性男性20年前列腺癌特异性死亡累积发生率为5.2%(95%CI 3.9-6.5)。
- PSA≤10 μg/L且初次活检良性者(2779人)20年前列腺癌特异性死亡累积发生率为0.7%(95%CI 0.2-1.3)。
- PSA>10且≤20 ng/mL者(855人)为3.6%(95%CI 0.1-7.2),PSA>20 ng/mL者(454人)为17.6%(95%CI 12.7-22.4)。
核心结论
- 初次系统性经直肠超声引导活检组合提供重要预后信息。
- 初次活检良性男性20年前列腺癌特异性死亡风险低。
- 研究结果对低PSA且初次活检良性的男性是否应进一步诊断评估提出疑问,鉴于其他原因死亡风险高。
研究设计与样本
- 基于丹麦前列腺癌登记处(基于人群的登记处,包括所有接受前列腺组织病理学评估的男性)的基于人群研究。
- 纳入1995年1月1日至2011年12月31日转诊行经直肠超声引导活检评估疑似前列腺癌的所有男性。
- 随访数据截至2015年4月28日。
- 主要终点为前列腺癌特异性死亡累积发生率,采用竞争风险分析,其他原因死亡为竞争事件。
主要发现
- 1995年1月1日至2011年12月31日,64430名男性转诊行经直肠超声引导活检,其中63454名符合纳入条件。
- 中位随访5.9年(IQR 3.8-8.5),总随访时间从1995年1月1日首例患者入组至2015年4月28日死因提取为20年。
- 35159名初次活检恶性男性中10407名(30%)死于前列腺癌,而27181名初次活检良性男性中541名(2%)死于前列腺癌。
- 估计20年总死亡率为76.1%(95%CI 73.0-79.2)。
- 所有转诊行经直肠超声引导活检男性中,20年前列腺癌特异性死亡累积发生率为25.6%(24.7-26.5),其他原因死亡为50.5%(47.5-53.5)。
临床怎么用
- 作者认为,初次系统性经直肠超声引导活检组合提供重要预后信息。
- 作者认为,初次活检良性男性20年前列腺癌特异性死亡风险低。
- 作者提出疑问:低PSA且初次活检良性的男性是否应进一步诊断评估,鉴于其他原因死亡风险高。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The risk of missing prostate cancer in the transrectal ultrasound-guided systematic biopsies of the prostate in men with suspected prostate cancer is a key problem in urological oncology. Repeat biopsy or MRI-guided biopsies have been suggested to increase sensitivity for diagnosis of prostate cancer, but the risk of disease-specific mortality in men who present with raised prostate-specific antigen (PSA) concentration and a benign initial biopsy result remains unknown. We investigated the risk of overall and prostate cancer-specific mortality in men with a benign initial biopsy set. METHODS: Data were extracted from the Danish Prostate Cancer Registry-a population-based registry including all men undergoing histopathological assessment of prostate tissue. All men who were referred for transrectal ultrasound-guided biopsy for assessment of suspected prostate cancer between Jan 1, 1995, and Dec 31, 2011, in Denmark were eligible for inclusion. Follow-up data were obtained on April 28, 2015. The primary endpoint was the cumulative incidence of prostate cancer-specific mortality, analysed in a competing risk setting, with death from other causes as the competing event. FINDINGS: Between Jan 1, 1995, and Dec 31, 2011, 64 430 men were referred for transrectal ultrasound-guided biopsy, of whom 63 454 were eligible for inclusion. Median follow-up was 5·9 years (IQR 3·8-8·5) and the total follow-up time, from the enrolment of the first patient on Jan 1, 1995, until the extraction of causes of death on April 28, 2015, was 20 years. 10 407 (30%) of 35 159 men with malignant initial biopsy sets died from prostate cancer, compared with 541 (2%) of 27 181 men with benign initial biopsy sets. Estimated overall 20-year mortality was 76·1% (95% CI 73·0-79·2). In all men referred for transrectal ultrasound-guided biopsy, the cumulative incidence of prostate cancer-specific mortality after 20 years was 25·6% (24·7-26·5) versus 50·5% (47·5-53·5) for mortality from other causes. In men with benign initial biopsy sets, the cumulative incidence of prostate cancer-specific mortality was 5·2% (3·9-6·5) versus 59·9% (55·2-64·6) for mortality from other causes. In men with PSA concentrations 10 μg/L or lower and benign initial biopsy sets (2779 men), the cumulative incidence of prostate cancer-specific mortality was 0·7% (0·2-1·3). Cumulative incidence of prostate cancer specific mortality in men with benign initial biopsy sets was 3·6% (95% CI 0·1-7·2) for men with a PSA higher than 10 ng/mL but 20 ng/mL or less (855 men) and 17·6% (12·7-22·4) and for men with a PSA higher than 20 ng/mL (454 men). INTERPRETATION: The first systematic transrectal ultrasound-guided biopsy set holds important prognostic information. The 20-year risk of prostate cancer-specific mortality in men with benign initial results is low. Our findings question whether men with low PSA concentration and a benign initial biopsy set should undergo further diagnostic assessment in view of the high risk of mortality from other causes. FUNDING: Capital Region of Denmark's Fund for Health Research, Danish Cancer Society, Danish Association for Cancer Research, and Krista and Viggo Petersen's Foundation.
引用
- Klemann N, Røder MA, Helgstrand JT, et al. Risk of prostate cancer diagnosis and mortality in men with a benign initial transrectal ultrasound-guided biopsy set: a population-based study. Lancet Oncol. 2017. PMID: 28094199. doi:10.1016/S1470-2045(17)30025-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。